Finance

Lists
BIOCON:NSE
Biocon Ltd
₹ ३४९.२०
-०.८०%
(-२.८०) 1D
अक्टोबर १६, १५:३०:०० GMT+५:३०  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
₹ ३५२.६०
High
₹ ३५३.००
Low
₹ ३४८.००
Mkt. cap
५.६९ खरब
Avg. vol.
२९.७४ लाख
Volume
१८.७६ लाख
Dividend
०.१४%
Quarterly dividend
₹ ०.१२
Ex-dividend date
२०२६ जुलाई ३
P/E ratio
१०३.३८
52-wk high
₹ ४४७.१५
52-wk low
₹ ३३७.७०
EPS
₹ ३.३८
Shares outstanding
६०.०० करोड
No. of employees
१६ हजार
Open
₹ ३५२.६०
High
₹ ३५३.००
Low
₹ ३४८.००
Mkt. cap
५.६९ खरब
Avg. vol.
२९.७४ लाख
Volume
१८.७६ लाख
Dividend
०.१४%
Quarterly dividend
₹ ०.१२
Ex-dividend date
२०२६ जुलाई ३
P/E ratio
१०३.३८
52-wk high
₹ ४४७.१५
52-wk low
₹ ३३७.७०
EPS
₹ ३.३८
Shares outstanding
६०.०० करोड
No. of employees
१६ हजार
News stories
From web sources and news partners
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees१६.४ हजार
Founded१९७८ नोभेम्बर २९
Headquartersबेङ्गलोर, कर्नाटक, भारत
Sector-
Websitebiocon.com
Last report
२०२६ अगस्ट ६
Fiscal period
Q1 2027
₹ ०.९५ / ₹ १.०९
-१२.६८%miss
Revenue / Est. (INR)
४३.३६ अरब / ४४.७४ अरब
-३.०८%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
४२.९६ अरब
४१.७३ अरब
४५.१७ अरब
४३.३६ अरब
Cost of goods sold
१७.७२ अरब
१३.३९ अरब
२३.६९ अरब
१४.६८ अरब
Cost of revenue
१७.७२ अरब
१३.३९ अरब
२३.६९ अरब
१४.६८ अरब
Research and development expenses
-१३.२० करोड
-५३.१० करोड
-१२.८० करोड
-१.६० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
९.५९ अरब
८.७५ अरब
१३.२८ अरब
९.१६ अरब
Operating expense
२१.१८ अरब
२५.१६ अरब
१४.४५ अरब
२५.६९ अरब
Total operating expenses
३८.९० अरब
३८.५५ अरब
३८.१४ अरब
४०.३६ अरब
Operating income
४.०५ अरब
३.१८ अरब
७.०३ अरब
३.०० अरब
Other non operating income
९.४० करोड
१.१७ अरब
-२.५२ अरब
५४.५० करोड
EBT including unusual items
१.७१ अरब
-६७.८० करोड
२.४८ अरब
१.२८ अरब
EBT excluding unusual items
१.२३ अरब
२.२६ अरब
१.८० अरब
१.४१ अरब
Income tax expense
३८.५० करोड
-१६.०० करोड
४८.९० करोड
-९.२० करोड
Effective tax rate
२२.४८%
२३.६०%
१९.७६%
-७.२१%
Other operating expenses
६.७२ अरब
११.७८ अरब
-४.१२ अरब
११.०७ अरब
Net income
८४.५० करोड
१.४४ अरब
१.२६ अरब
१.४१ अरब
Net profit margin
१.९७%
३.४५%
२.७९%
३.२५%
Earnings per share
०.७२
२.७४
१.२७
०.९५
Interest and investment income
२३.५० करोड
-
१.१५ अरब
-
Interest expense
-२.७२ अरब
-२.१० अरब
-२.०६ अरब
-२.१३ अरब
Net interest expenses
-२.४९ अरब
-२.१० अरब
-९०.६० करोड
-२.१३ अरब
Depreciation and amortization charges
४.७३ अरब
५.१५ अरब
५.१३ अरब
५.४७ अरब
EBITDA
८.६९ अरब
७.१३ अरब
११.६२ अरब
७.५९ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google एपहरू